Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506517 | 0.91 | SRD5A2 (0.57) | CES2CES1RAB9AHTR2AHTR2C | |
| SCHEMBL27458452 | 0.85 | HTR2A (0.51) | NPC1RAB9AHTR2AHTR2CHTR7 | |
| SCHEMBL19754954 | 0.83 | KMT2A (0.53) | NPC1RAB9AHTR2AHTR2CHTR7 | |
| SCHEMBL3678830 | 0.80 | MGLL (0.56) | NPC1RAB9AHTR2AHTR2CHTR7 | |
| SCHEMBL14156622 | 0.80 | CA1 (0.53) | NPC1RAB9AHTR2AHTR2CHTR7 | |
| SCHEMBL7498931 | 0.80 | HDAC3 (0.50) | NPC1RAB9AHTR2AHTR2CHTR7 | |
| SCHEMBL2763119 | 0.78 | KMT2A (0.56) | NPC1RAB9AHTR2AHTR2CHTR7 | |
| SCHEMBL31719066 | 0.78 | HTR2A (0.44) | CES2CES1HTR2AHTR2CHTR2B | |
| SCHEMBL3681499 | 0.77 | CA2 (0.52) | NPC1RAB9AHTR2AHTR2CHTR7 | |
| SCHEMBL13084751 | 0.77 | NPC1 (0.49) | NPC1RAB9AHTR2AHTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3585775-B1 | AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2022-04-06 | — | — | EP | disclosed |
| US-10392366-B2 | Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2019-08-27 | — | — | US | disclosed |
| WO-2018153849-A1 | AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2018-08-30 | — | — | WO | disclosed |
| US-20180237419-A1 | AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2018-08-23 | — | — | US | disclosed |
| US-20170369440-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(CYCLOPROPANECARBONYL)PHENYL]-2-METHYL-PROPANENITRILE | EUROAPI GERMANY GMBH (DE) | 2017-12-28 | — | — | US | disclosed |
| WO-2016116555-A1 | Process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-07-28 | — | — | WO | disclosed |
| EP-2261208-A1 | Intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives | Aventisub II Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261207-A1 | Intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives | Aventisub II Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-1953142-A1 | Process for the preparation of antihistaminic 4-diphenylmethyl piperidine derivatives | Aventis Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1446385-A1 | PREPARATION AND USE OF SUBSTITUTED IMIDAZOLES | NOVO NORDISK A/S (DK) | 2004-08-18 | — | — | EP | disclosed |
| US-20020007085-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2002-01-17 | — | — | US | disclosed |
| US-20010031895-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL DOW PHARMACEUTICALS INC. | 2001-10-18 | — | — | US | disclosed |
| US-20010021791-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2001-09-13 | — | — | US | disclosed |
| US-20010020114-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2001-09-06 | — | — | US | disclosed |
| US-20010018521-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2001-08-30 | — | — | US | disclosed |
| US-6242606-B1 | REACTING A A,A-DIMETHYLPHENYLACETIC ACID AMIDE WITH A W-HALO COMPOUND PRODUCES W'-HALO-A-KETO-A,A-DIMETHYLPHENYLACETIC ACID AMIDE AND REACTING IT WITH A PIPERIDINE COMPOUND; 2-(4-(4-CHLORO-BUTYRYL)-PHENYL)-2-METHY-PROPIONIC ACID | MERRELL PHARMACEUTICALS INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010000038-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | CHATTEM INC. | 2001-03-15 | — | — | US | disclosed |
| US-6147216-A | Intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0705245-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF ANTIHISTAMINIC 4-DIPHENYLMETHYL/DIPHENYLMETHOXY PIPERIDINE DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000480-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF ANTIHISTAMINIC 4-DIPHENYLMETHYL/DIPHENYLMETHOXY PIPERIDINE DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000038-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | CES2 1120/4885CES1 497/4885NPC1 2412/4885 |
| US-20010020114-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | CES2 1758/4885CES1 512/4885NPC1 2390/4885 |
| US-20010021791-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | CES2 1027/4885CES1 437/4885NPC1 1689/4885 |
| US-20010031895-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH4, HRH3 | CES2 900/4885CES1 388/4885NPC1 1692/4885 |
| US-10392366-B2 | Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | GPR119, GPR39, GPR139 | CES2 1718/4885CES1 389/4885NPC1 137/4885 |
| US-20010018521-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | CES2 1053/4885CES1 425/4885NPC1 2104/4885 |
| US-20020007085-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | CES2 934/4885CES1 417/4885NPC1 1740/4885 |
| US-20180237419-A1 | AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, GIPR, GPR39 | CES2 2344/4885CES1 796/4885NPC1 208/4885 |
| US-20170369440-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(CYCLOPROPANECARBONYL)PHENYL]-2-METHYL-PROPANENITRILE | CYP4B1, CYP3A4, CYP4F2 | CES2 1301/4885CES1 2081/4885NPC1 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.